Francisco focuses on Bio-IT investments and Enterprise AI.
Francisco previously was the Resident Data Scientist at Formation 8, where he worked with portfolio companies to strategize, prototype, and recruit for data products. He was the founder of Catenus Science, a data science consulting and recruiting firm that used an apprenticeship model to help early stage companies build data science teams.
Francisco received his Ph.D. in Biomedical Informatics from Stanford, where he was a Ruth L. Kirchstein Fellow. His research focused on clinical decision support for Radiology, which won him the Martin Epstein award for best paper at the American Medical Informatics Association in 2014. He was the commencement speaker for the Stanford School of Medicine in 2015.
He earned his BS in Electrical Engineering and Computer Sciences from UC Berkeley while doing research in Parkinson’s disease at UCSF.
What’s a Rich Text element?
The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.
Static and dynamic content editing
A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!
How to customize formatting for each rich text
Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.
The Crisis and Opportunity in Rare Diseases
8VC stepped into life sciences to bridge the gap between groundbreaking biomedical innovation and real-world patient care. Our collaborations with visionary scientists have already begun transforming deadly diseases into manageable conditions, and in some cases, outright cures. Despite the immense potential of advanced diagnostics and therapies, however, rare disease medicine remains starkly underdeveloped. At their core, the unmet needs in rare diseases are not only scientific or medical challenges, but fundamental misalignments of commercial and societal incentives.
The Crisis and Opportunity in Rare Diseases
8VC stepped into life sciences to bridge the gap between groundbreaking biomedical innovation and real-world patient care. Our collaborations with visionary scientists have already begun transforming deadly diseases into manageable conditions, and in some cases, outright cures. Despite the immense potential of advanced diagnostics and therapies, however, rare disease medicine remains starkly underdeveloped. At their core, the unmet needs in rare diseases are not only scientific or medical challenges, but fundamental misalignments of commercial and societal incentives.
Announcing Our Investment in Photys Therapeutics
We’re pleased to announce 8VC’s participation in the $75 million Series A for Photys Therapeutics, led by MPM Capital and joined by Omega Funds, Longwood, Arkin Bio, Mass General Brigham Ventures, MRL Ventures Fund, Eli Lilly and Company, and Heritage Medical Systems.
Announcing Our Investment in Photys Therapeutics
We’re pleased to announce 8VC’s participation in the $75 million Series A for Photys Therapeutics, led by MPM Capital and joined by Omega Funds, Longwood, Arkin Bio, Mass General Brigham Ventures, MRL Ventures Fund, Eli Lilly and Company, and Heritage Medical Systems.
The Year That Changed Medicine Forever | Francisco Gimenez Explains the Biotech Revolution
The Year That Changed Medicine Forever | Francisco Gimenez Explains the Biotech Revolution
8VC’s Investment in Mantra Bio
Paul Ehrlich, one of the forefathers of modern medicine, famously proposed the idea of a “magic bullet” that would selectively kill pathogens while sparing the body. His research led to the first drug for syphilis and established the chemistry-driven paradigm of therapeutics that would persist for the next 70 years. Unfortunately, it turned out that there is no simple way to achieve arbitrary targeting of cytotoxic chemical compounds, and these magic bullet treatments proved difficult to reproduce. The lack of precision delivery presents pharma with a double-edged sword: higher doses with elevated toxicity, or lower doses that are potentially inefficacious.
8VC’s Investment in Mantra Bio
Paul Ehrlich, one of the forefathers of modern medicine, famously proposed the idea of a “magic bullet” that would selectively kill pathogens while sparing the body. His research led to the first drug for syphilis and established the chemistry-driven paradigm of therapeutics that would persist for the next 70 years. Unfortunately, it turned out that there is no simple way to achieve arbitrary targeting of cytotoxic chemical compounds, and these magic bullet treatments proved difficult to reproduce. The lack of precision delivery presents pharma with a double-edged sword: higher doses with elevated toxicity, or lower doses that are potentially inefficacious.
Announcing Our Investment in Orca Bio
Every year in America, roughly 23,000 people undergo a Bone Marrow Transplant (BMT). These procedures are typically last-line interventions to save cancer patients. When successful, the therapy is often curative.
Announcing Our Investment in Orca Bio
Every year in America, roughly 23,000 people undergo a Bone Marrow Transplant (BMT). These procedures are typically last-line interventions to save cancer patients. When successful, the therapy is often curative.
.png)